Vik Seoni, Vice President, Business Development, Endo PharmaceuticalsRobert Bloder, Vice President, Business Development, Aveva Drug Delivery Systems, Inc.
*A few of the products mentioned during this presentation:
New Product Approvals:
Last year was an eventful year in the marketplace, the approvals that came in the fourth quarter. Nucynta was approved. It’s immediate release and it’s for moderate to severe acute pain in patients >18 years of age. There is also another product in the pipeline that has tamper resistant elements.
Qutenza – 8% capsaicin patch. First and only prescription for neuropathic pain associated with PHN. Single application can reduce pain for up to 12 weeks. Also approved in Europe where Astellas will market. The product application will be interesting. It’s not a patch to wear and walk off with, there is a several hour procedure where the product is applied. Once the application process finished, you can wear the product for several weeks.
Pennsaid – Covidien
Topical solution for diciofenac, for the signs and symptoms of OA of the knee. Pennsaid Plus Gel is the follow-on product in development.
Onsolis – Meda
Fentanyl in BEMA delivery technology for treatment of breakthrough cancer pain in patients tolerant of opiods
-REMS program
-Distributed to patients through specialty pharmacies via courier
-Patients receive a call from healthcare professional to ensure proper use
|
Share this article with your social network, just click below to share now!
|
|
|
No comments :
Post a Comment